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Results

Abstract
Breast cancer has the highest incidence rate of all cancers globally in women, and
those of African descent, especially West African females, face higher rates of triplenegative breast cancer (TNBC), a more aggressive form of breast cancer.
Immunotherapy for breast cancer is a relatively new treatment option, and research is
ongoing to identify the best combination of treatments for increasing survival of those
diagnosed with TNBC. Eganelisib (IPI-549: a PI3K-gamma inhibitor) shifts
immunosuppressive M2 macrophages to stimulatory M1 type and has been shown
to augment T cell function; combined with other treatments, it has shown
promising results in reducing tumor growth and increasing survival in tumorbearing mice. We have been conducting experiments to determine the most effective
treatment regimen that will reduce growth of 4T1 mammary cancers, a murine TNBC
model in syngeneic Balb/C female mice. Combinations of eganelisib, cyclophosphamide,
and anti-PD-1 have been tested to determine how immunotherapy and chemotherapy
can induce a strong immune response, resulting in better responses to the treatment.
Our current data indicates that a treatment regimen combining eganelisib,
cyclophosphamide, and anti-PD-1 was most effective at suppressing tumor
growth, compared to other regimens that only included one or two of these
treatments. Mean tumor sizes of mice treated with a combination of eganelisib and
other treatments were 187±70 mm3, 232±71 mm3, and 227±59 mm3 at the end of the
experiments, compared to untreated control tumors of 576±137 mm3, 414±31 mm3, and
591±200 mm3, respectively. These results could lead to further research on effective
immunotherapy treatment combinations for TNBC.
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Syngeneic Balb/C female mice are used for the studies, and on day 0, 50,000 cells
from the 4T1 breast cancer cell line are injected into the mammary fat pads of each
mouse. The current treatments being tested include eganelisib, cyclophosphamide, and
anti-PD-1. Eganelisib is administered through oral gavage at a dosage of 0.2 mg/kg or
0.3 mg/kg on days 7-11 and days 14-18 of the experiment. Cyclophosphamide and
anti-PD-1 are administered through intraperitoneal injections in the quadrant opposite
that of the one where the cancer cells were injected. Cyclophosphamide was given at
100 mg/kg, and different timings of cyclophosphamide administration were tested
(either day 7 or day 11) to determine the most effective sequence. Anti-PD-1 was
administered to the mice at 100 μg/mouse every three to four days until the end of the
treatment regimen.
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All the experiments conducted showed that a combined approach of
eganelisib with anti-PD-1 and/or cyclophosphamide was effective in
decreasing tumor growth. When eganelisib was given at a dose of 0.2
mg/kg, along with anti-PD-1, the final average tumor volume was 187±70
mm3, compared to 576±137 mm3, the final average tumor volume of the
control group. Similarly, when the same dosage of eganelisib was
combined with anti-PD-1 and cyclophosphamide in a different
experiment, the final average tumor volume of the experimental group
that received all three treatments was 232±71 mm3, compared to the
control group’s tumor volume of 414±31 mm3. Increasing the dosage of
eganelisib from 0.2 mg/kg to 0.3 mg/kg and administering
cyclophosphamide at day 11 instead of day 7 seemed to have an effect
on tumor growth - the tumor volume of the experimental group that
received this increased dosage of eganelisib and different treatment
sequencing of cyclophosphamide with the addition of anti-PD-1 had an
average tumor volume of 227±59 mm3, while the untreated control group
had a mean tumor volume of 591±200 mm3. The survival in the
experimental group showed more promise compared to the control group
mice.
These results show that the sequence of the treatment regimen may play
a role on the impact on tumor volume, as well as overall survival.
Studying when cyclophosphamide is administered can improve results for
decreasing tumor growth by strengthening the immune microenvironment
of the tumor. It may be that increasing the immune response prior to
chemotherapy may increase the efficacy of the latter. Alternatively,
cyclophosphamide, which has been found by some to selectively deplete
immunosuppressive Treg cells may increase the efficacy of the immune
therapies. Future experiments with different sequences of the same
treatments can further reveal the impact of timing for establishing
effective treatment regimens that will decrease or even stop tumor growth
and increase survival of mice with breast cancer.
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Immune checkpoint inhibitors (ICI), such as anti-PD-1 or anti-PD-L1, have been in the
process of development as possible treatment options for TNBC and HER2+ breast
cancers. Some have suggested that tumors with high levels of tumor-infiltrating
lymphocytes may be most likely to benefit from ICI treatment. PI3Kγ inhibitors, such as
eganelisib (IPI-549), are also used in our studies to test its efficacy for reducing tumor
growth when given in conjunction with chemotherapy and ICI. In studies with myeloid
cells, a correlation between immune checkpoint blockade resistance and increase of
immune-suppressive myeloid cells/macrophages warranted a need for an agent that
would enhance the tumor immune microenvironment and overcome resistance to
immune checkpoint blockade. As PI3Kγ signaling plays a role in suppressing immune
response and promoting tumor growth, a PI3Kγ inhibitor, such as eganelisib, could
improve immune responses by decreasing M2 macrophages and increasing the activity
of CD8+ T cells and increasing cytotoxicity in the immune microenvironment.

Cyclophosphamide (100 mg/kg)
Day 7 or Day 11

Treatment Regimen

Days vs aPD1, CYP
Days vs Egan, aPD1
Days vs Egan, aPD1, CYP

30

40

